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The landscape of diagnostic testing for tuberculosis (TB)
is changing rapidly, and stakeholders need urgent
guidance on how to develop, deploy and optimize TB
diagnostics in a way that maximizes impact and makes
best use of available resources. When decisions must be
made with only incomplete or preliminary data avail-
able, modelling is a useful tool for providing such
guidance. Following a meeting of modelers and other
key stakeholders organized by the TB Modelling and
Analysis Consortium, we propose a conceptual frame-
work for positioning models of TB diagnostics. We use
that framework to describe modelling priorities in four
key areas: Xpertw MTB/RIF scale-up, target product
profiles for novel assays, drug susceptibility testing to
support new drug regimens, and the improvement of
future TB diagnostic models. If we are to maximize the
impact and cost-effectiveness of TB diagnostics, these
modelling priorities should figure prominently as targets
for future research.
K E Y WORD S : tuberculosis; modelling; diagnostics
THE FUTURE OF DIAGNOSTIC TESTING for
active tuberculosis (TB) has never been more prom-
ising. In addition to the Xpertw MTB/RIF assay
(Cepheid, Sunnyvale, CA, USA), a number of other
promising assays are being evaluated in trials,1 and
profiles for next-generation diagnostic tests are being
developed.2 Novel regimens for anti-tuberculosis
treatment are being launched,3 and corresponding
diagnostics for drug susceptibility testing (DST) have
emerged as a priority.4 For the first time, tests capable
of detecting 80% of all cases of pulmonary TB—
including DST profiles—may become reality.5 As
these tests emerge, the need to understand their
potential impact and cost-effectiveness has never been
more urgent. These emerging diagnostic tests will
likely be much more expensive than sputum smear
microscopy, and the effects of their introduction into
health systems (with existing algorithms and patterns
of clinical/empiric diagnosis) are unclear.6,7 Ultimate-
ly, we must strive to leverage these tests in a way that
improves population health, using scarce economic
resources as carefully as possible. In the context of
incomplete data and urgent decision-making time-
lines, models may play an invaluable role.8 Models
commonly used to evaluate TB diagnostics include
epidemiological transmission models,9 economic
evaluation models10 and health system models.11
Conclusions from all such models are subject to
uncertainty, as data that inform estimates of param-
eter values are limited and our knowledge of the
natural history of TB is incomplete. Where popula-
tion-level data on the impact of interventions do not
exist, models are often the only way to translate
existing empirical data into projections of impact and
cost-effectiveness for decision-making purposes.
It is in this environment that the TB Modelling and
Analysis Consortium (TB MAC) held its second
meeting on the ‘impact and cost-effectiveness of
current and future TB diagnostics’ in Amsterdam,
The Netherlands, in April 2013 (Table 1). The aim of
this meeting was to advance modelling efforts in four
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major areas identified as priorities through collabo-
rative pre-meeting discussions:
1 Informing scale-up strategies for Xpert
2 Developing and setting target product profiles
(TPPs) for novel TB assays
3 Understanding the role of DST in existing and
novel TB drug regimens
4 Describing analytical and modelling needs for
better models of TB diagnostics.
Although other needs for modelling TB diagnostics
exist, these four ‘streams’ were felt to represent
focused areas in which well-designed models could
have an important and rapid impact on urgent policy
decisions.
MODELLING TB DIAGNOSTIC TESTS: A
CONCEPTUAL FRAMEWORK
We developed a conceptual framework to help
position models of TB diagnostic testing. In this
framework (Figure), models generally consider diag-
nostics at a point along the timeline from develop-
ment (future tests), to deployment (recently released
tests), to optimization (existing tests). This timeline is
an iterative one; for example, optimization can
inform future deployment efforts, and both can
inform development of the next generation of novel
tests. The outcomes of these modelling analyses may
include different combinations of epidemiology
(population level impact), implementation (patient
and health system impact), and economics (resource
requirements and cost-effectiveness). Thus, for ex-
ample, a model of hypothetical cost-effectiveness of
diagnostics12 may position itself to the far lower left
of this grid, whereas an Xpert scale-up model within
populations and health systems11 may position itself
to the mid-upper right.
WORKSTREAM PRIORITIES
After constructing the conceptual framework above,
we developed a list of priorities in each of the four
streams for which models could improve decision
making and ultimately population health (Table 2).
Stream 1: Informing scale-up strategies for Xpert MTB/
RIF
Given the rapid global scale-up of Xpert,13 there is
considerable pressure for country-level policy makers
to decide if and how to introduce and/or scale upXpert
within existing programs. High-quality evidence exists
as to the accuracy of Xpert,5 but to quantitatively
project the population-level impact and cost-effective-
ness of different Xpert scale-up strategies, estimates of
numerous other parameters (e.g., rates of TB trans-
mission, diagnosis and mortality) must be incorporat-
ed into a unified modelling framework.14 Models that
provide evidence-based estimates of cost and/or
avertible morbidity and mortality under different
implementation policies would provide valuable plat-
forms to guide rational decision making (Figure,
column 2, rows 1–3). In most cases, however, policy
decisions related to Xpert implementation are made
without the benefit of such model-based guidance. A
small number of existing models have indicated that
Table 1 TB Modelling and Analysis Consortium (TB MAC): diagnostics meeting structure
Planning for this meeting of 50 participants began more than 6 months in advance, with discussions among an eight-member steering
committee including transmission modelers, economists, epidemiologists, and representatives from the funding agency (Bill and Melinda
Gates Foundation). Through these discussions, a series of four ‘workstreams’ was envisioned; these streams were selected as meeting three
criteria:
1) They must address an urgent near-term need, questions of which are amenable to modelling
2) a body of empirical and/or conceptual work to support models must be emerging, and
3) sufficient future (financial and political) support for models must be feasible.
Each stream was assigned:
1) a short-term deliverable (usually a list of priorities) to be completed by the end of the 2-day workshop
2) a long-term deliverable (either a scientific paper or a modelling project) to be completed within a set time period, and
3) an invited chairperson.
Before the meeting, the following steps were taken:
1) potential funding sources were identified to enable each stream to complete the long-term deliverables
2) a participant list consisting of modelers, epidemiologists, key stakeholders and trainees was developed; all meeting participants were
asked to select a stream for primary participation
3) each stream chair was asked to coordinate a pre-meeting conference call among participants who selected to participate in that
stream
4) a systematic literature review (to be reported elsewhere, summary available at: www.tb-mac.org/resources) was commissioned to
describe existing epidemiological and economic models of TB diagnostic tests.
During the meeting, each stream (under the direction of the chairperson) coordinated:
1) a series of scientific presentations to the full group
2) a breakout session for initial planning
3) a report back to the full group of participants
4) a second breakout session for meeting the assigned deliverables and
5) a final summary of progress.
TB¼ tuberculosis.
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Xpert scale-up is likely to be cost-effective (using
conventional thresholds of willingness to pay) in a
limited number of settings.14–18 However, these
models may not be generalizeable, and in areas with
severe resource constraints, anti-tuberculosis treat-
ment may be relatively cheap, whereas Xpert may be
less affordable, thereby generating high opportunity
costs for Xpert-based diagnosis.19 Furthermore, scale-
up of Xpert may entail massive downstream costs,
including treatment for multidrug-resistant TB20 and
long-term human immunodeficiency virus (HIV)
therapy for people cured of TB.21 Models must also
consider the additional costs of embedding Xpert
effectively within health systems (e.g., power and
climate control, staff retraining and backup systems
when equipment fails).
Against this background, we present a list of high-
priority questions that should be addressed in model-
based analyses of Xpert scale-up, including questions
related to epidemiology, health systems and economic
impact (Table 2). A key consideration is the out-
standing need for setting-specific models that are
calibrated to existing epidemiological data (e.g., TB
incidence, HIV prevalence and multidrug-resistant
TB [MDR-TB] prevalence) and structured to consider
practical details related to health system access and
diagnostic pathways for TB. These features are
important in guiding the best approach for Xpert
scale-up within existing programs (Questions 1 and
2), determining how modifications of existing path-
ways to diagnosis and care can be modified to
maximize the benefits of Xpert (Question 3) and
understanding how Xpert scale-up might affect broad
resource needs (e.g., MDR-TB or HIV treatment
capacity) (Question 4). In summary, new models
addressing these priority needs would facilitate
country-level decision making by providing quanti-
tative, evidence-based comparisons of alternative
strategies for Xpert scale-up. Critical to the success
of these models is early and ongoing engagement with
local organizations (e.g., national tuberculosis pro-
grams) that are tasked with actual scale-up decisions.
Stream 2: Developing and selecting target product
profiles for novel TB assays
There is currently great industry interest in TB
diagnostics, with more than 50 companies actively
developing TB diagnostic technologies.22 This inter-
est reflects many unmet needs. Not only is Xpert too
expensive and infrastructure-dependent to be widely
deployed in decentralized settings,23 we also lack
good tests for latent tuberculous infection, and extra-
pulmonary and childhood TB. Given these pressing
needs, it is essential to guide test developers as to
which assays will have the greatest impact on TB
epidemiology, health systems/clinical care and eco-
nomic considerations (i.e., Figure, column 1, rows 1–
3). By comparing assays with different niches and
different specifications according to these three
classes of outcomes, models can help test developers
focus on those products likely to have not only the
largest market but also the most potential to reduce
Figure A conceptual framework for models of current and future TB diagnostic tests. Models
can be positioned along a spectrum of development-deployment-optimization on one axis and an
interface between outcomes related to epidemiology, health systems and economics on the other.
Models can address more than one box at a time; representative modelling questions are provided,
although others might reasonably be posed. TB¼ tuberculosis.
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disease burden. One mechanism for providing such
guidance is through the development of TPPs, which
are widely used in the pharmaceutical industry to
focus drug development on key attributes.24,25 TPPs
are being developed for a wide array of TB diagnostic
tests, and well-designed models can guide developers
as to which new TB tests need to be prioritized for
development and, within those TPPs, those attributes
that are of critical importance.26
Of particular importance is a working definition of
point-of-care (POC) testing.2 Whereas most current
definitions of a POC test are product-oriented (e.g., a
simple, low-cost dipstick deployable in the commu-
nity), we argue that the most critical goal of a POC
testing process is to ensure rapid treatment, as
treatment is required to improve patient health and
reduce transmission. Thus, we propose a new
definition of POC testing for TB, i.e., testing that
will result in a clear, actionable management decision
within the same clinical encounter. This goal-oriented
definition suggests that TPPs should explicitly de-
scribe a test’s clinical purpose (e.g., triage, diagnosis
of pulmonary TB, DST); therapeutic goal (e.g., same-
day treatment initiation); target population (e.g.,
children, community-dwelling adults, HIV clinic);
level of implementation (home, community, clinic,
peripheral laboratory, hospital); and likely users.
In response to this need, we identified a list of 10
potential TPPs that well-designed comparative mod-
els could prioritize (Table 2). Once priority TPPs are
selected, more focused models can prioritize further
among the various attributes included in the TPP,
such as accuracy, turnaround time, price, patient
acceptability (e.g., blood and urine more often
Table 2 Modelling priorities: diagnostic tests for active TB
Stream 1 — Informing scale-up strategies for XpertW MTB/RIF
What are the most important modelling questions related to Xpert scale-up that are likely to remain unanswered by 2014?
1) How can Xpert infrastructure best be deployed within a country?
2) Which population groups and clinical contexts represent the highest impact targets for Xpert?
3) What are priority aspects of TB diagnosis and treatment programs to be strengthened to maximize the impact of Xpert?
4) How might Xpert implementation affect the uptake, use, and resource needs of related health services?
Stream 2 — Developing and selecting TPPs for novel TB assays
What TPPs should be compared and refined with well-designed models?
1) Triage test for those seeking care, to identify individuals who require confirmatory testing for pulmonary TB
2) HIV clinic-based test to rule out active TB and facilitate same-day initiation of preventive therapy in HIV-infected persons
3) Systematic screening test (provider-initiated) for active case finding that targets people who may not seek care
4) Rapid sputum-based, cartridge-based, molecular test for microscopy centers (with the option of add-on DST)
5) Rapid biomarker-based, instrument-free test for non-sputum samples that can also detect childhood and extra-pulmonary TB
6) Multiplexed test for TB and other infectious diseases
7) Centralized, high-throughput DST incorporating new drugs to support the roll-out of new anti-tuberculosis treatment regimens
8) Treatment monitoring test (test for cure)
9) Predictive test for latent tuberculous infection progressing to active TB
10) Home-based unsupervised self-test for TB that is extremely simple and will trigger self-referrals
Stream 3 — Understanding the role of DST in existing and novel TB regimens
What scenarios/algorithms should be explored for development and deployment of DST assays?
Scenarios:
1) High MDR-TB prevalence/all people with suspected or confirmed TB
2) High MDR-TB prevalence/retreatment or failure cases only
3) Low MDR-TB prevalence/all people with suspected or confirmed TB
4) Low MDR-TB prevalence/retreatment or failure cases only
Algorithms:
1) RMP, then FQ (6 PZA)
2) RMP and FQ, then PZA
3) RMP, FQ and PZA (‘front-loaded’)
4) Algorithms including novel chemical entities
Stream 4 — Describing analytical and modelling needs for better models of TB diagnostics
What improvements to models, if implemented, would improve predictions of the impact of TB diagnostics?
Feasible improvements in data
1) Evaluating when in the course of disease transmission (leading to secondary cases) occurs, vs. timing of (active or passive) diagnosis,
treatment initiation and treatment completion, including losses to follow-up
i) Time course of infectiousness and symptoms
ii) Time course of contacts of susceptible individuals
2) Measuring the number, quality, and timing of interactions with the health system (including losses to follow-up) from the start of the
course of TB disease
3) Establishing the resource requirements and patient costs associated with each interaction
i) Including affordability/health system spend
Feasible improvements in model structure
1) Further developing health systems models to understand health systems questions and link to cost, cohort, and transmission models
2) Creating user-friendly models.
TB¼ tuberculosis; TPP¼ target product profiles; HIV¼human immunodeficiency virus; DST¼drug susceptibility testing; MDR-TB¼multidrug-resistant TB; RMP¼
rifampin; FQ¼ fluoroquinolones; PZA¼ pyrazinamide.
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preferred over sputum) and the ability to be deployed
within existing health systems as part of a POC
testing program. Ultimately, TPP development and
modelling represent an iterative process, with models
helping to refine and compare each successive TPP as
knowledge and prototypes emerge.
Stream 3: Understanding the role of drug susceptibility
testing in existing and novel TB regimens
With several new TB drugs in the pipeline, the
prospect of a first-line treatment regimen against
which no resistance exists may eventually become a
reality.24 More immediately, shortened first-line
regimens based on combinations of current and
repurposed TB drugs are emerging.4 Fluoroquino-
lone-based regimens are of particular interest, and a
clinical trial was recently initiated based on the early
bactericidal activity of a regimen in which the novel
nitroimidazo-oxazine PA-824 is combined with mox-
ifloxacin and pyrazinamide (PaMZ).27 As many
novel regimens rely heavily on fluoroquinolones and
pyrazinamide (PZA), they may need to be restricted
to patients with organisms susceptible to these drugs;
unlike for rifampin (RMP), stand-alone DST for these
two drugs currently does not exist. DST against PZA
is particularly difficult, as phenotypic testing requires
acidic conditions, and genotypic testing must account
for over 200 mutations (mostly in a single gene,
pncA) potentially associated with resistance.28 It is
therefore important to specify the DST assays most
urgently needed for development (e.g., combined
assay for RMP, fluoroquinolones and PZA resistance
vs. stand-alone tests for each drug) and the most
important assay attributes, including accuracy, infra-
structure and biosafety requirements, and price. In
other words, we need a TPP for next-generation DST.
In addition to assay development, it is also critical to
understand how these assays should best be deployed.
For example, must all individuals receiving a novel
first-line regimen be tested for full susceptibility or
can we restrict testing to people at high risk for drug
resistance (e.g., RMP-resistant on Xpert, previously
treated for TB) and/or death (e.g., HIV)? These
questions of optimal DST assay development and
deployment can be answered by assessing the impact
of each alternative on epidemiology, health systems
and economics (Figure, column 1, rows 1–3). Models
provide a quantitative, structured mechanism for
making such comparisons.
We propose that these questions be addressed over
both short-term horizons (informing urgent policy
decisions) and longer-term ones (informing sustain-
able approaches), acknowledging that epidemics of
drug-resistant TB are often slow to emerge.29 We
define a series of clinically oriented scenarios and
assay-oriented algorithms that should be considered
by models (Table 2). For shorter horizons (e.g., 5
years), decision analytic models could assess the
implementation and cost-effectiveness (i.e., health
systems and economic impact) of these scenario-
algorithm combinations for both RMP-containing,
fluoroquinolone-based regimens and realistic RMP-
free regimens (e.g., PaMZ). For longer horizons (e.g.,
20–50 years), dynamic models incorporating assump-
tions about TB transmission could compare the
epidemiological impact on the emergence of drug-
resistant TB, considering also regimens of entirely
novel compounds. Ultimately, as with Xpert scale-up,
these questions must be answered in a variety of
epidemiological and economic settings, and in close
communication with the relevant stakeholders.
Stream 4: Describing analytical and modelling needs
for better models of TB diagnostics
As demonstrated by our systematic review (TB MAC
2: review of TB diagnostic modelling, available at
www.tb-mac.org/resources), current models of TB
diagnostics have a limited literature base on which to
draw. Existing transmission models of TB diagnosis
suffer from fundamental parameter and structural
uncertainties, including questions regarding the
amount of transmission that occurs before patients
seek diagnosis, the trajectory of infectiousness over
time and effects of contact structure on the timing of
transmission.30 Data are also scarce as to how
patients access diagnostic testing within existing
health systems (e.g., public vs. private sector diagno-
sis) and how diagnostic test results subsequently
affect outcomes (e.g., if patients are lost to care before
receiving test results). From the economic perspec-
tive, there is also a dearth of geographically repre-
sentative data on the costs of key TB diagnostic assays
and the costs incurred by patients specifically during
the diagnostic process, despite recent systematic
reviews31–33 of the overall costs to patients of health
care seeking for TB. These questions are particularly
relevant to deploying emerging tests and optimizing
existing diagnostic algorithms (Figure, columns 2–3).
We identified a set of critical analytical and
modelling needs required to improve existing models
of TB diagnostics (Table 2). First, we need to more
clearly understand when TB transmission occurs
relative to the timing of diagnosis, treatment initia-
tion, and losses to follow-up. For example, howmuch
transmission occurs between a missed diagnosis and
subsequent diagnosis leading to treatment initiation?
How much transmission can be averted through
active TB screening? We disaggregate these consider-
ations into biological and behavioral components;
specifically, we lack data on how symptoms and
infectiousness evolve over an individual’s disease
course, and on how contact patterns and care-seeking
behavior differ over time and space. Studies to fill
these gaps could include intensified evaluations of
contact networks and outbreaks linking records of
patient behavior with advanced molecular epidemi-
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ology (e.g., whole-genome sequencing) to better
pinpoint the timing of transmission and disease.34
Second, we need a better understanding of how TB
patients interact with the health system during the
diagnostic process, including the number, type and
timing of interactions (and losses to follow-up) within
that system over their disease course (Figure, row 2).
Detailed data on health service utilization might be
better collected during pragmatic clinical trials of TB
diagnostics,35 including more detail on the pathways
of those patients lost to care. Third, to better inform
economic evaluations (Figure, row 3), we need better
data on health systems resource requirements and
patient costs associated with TB diagnosis. To meet
this need, we cannot conduct costing studies in each
country, but well-selected, comprehensive costing
studies in different regions and income levels, coupled
with econometric models to extrapolate data to other
settings, could be invaluable. Two priority model-
development needs identified were improved health
systems models to better assess the operational
placement of new TB diagnostics, and user-friendly
models for decision making at the country level.
SUMMARY: MODELLING CURRENT AND
FUTURE TB DIAGNOSTICS
In the rapidly shifting landscape of TB diagnosis,
stakeholders—including industry leaders, policy
makers and implementers—need data-driven guid-
ance about which assays to develop, how to deploy
emerging assays within existing health systems, and
how to optimize existing assays and algorithms in the
field. These decisions must maximize the impact of
diagnostics on epidemiology, health systems and
clinical management using tightly constrained re-
sources. The urgency of the decision-making process
greatly outpaces our present ability to collect
definitive data on these outcomes. As such, models
serve a key role. We present a conceptual framework
for models of TB diagnostics (Figure) and define
modelling priorities in four streams (Table 2). In an
environment characterized by urgent questions and
severe resource constraints, this framework may help
guide data gathering and modelling efforts, with the
ultimate goal of enabling decision makers to develop,
deploy and optimize TB diagnostics in a way that
maximizes impact and effectively translates resources
into better health.
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R E S UM E
Le paysage des tests de laboratoire de la tuberculose
(TB) change rapidement et les parties prenantes ont
besoin de directives urgentes sur la manie`re d’e´laborer,
de diffuser et d’optimiser le diagnostic de la TB de fac¸on
a` maximiser son impact et faire le meilleur usage des
ressources disponibles. Quand il faut prendre des
de´cisions base´es sur les donne´es incomple`tes ou
pre´liminaires qui sont les seules disponibles, la
mode´lisation est un outil utile pour fournir ce type de
directive. A la suite d’une re´union de mode´lisateurs et
d’autres intervenants majeurs organise´e par le « TB
Modelling and Analysis Consortium ’, nous proposons
un cadre conceptuel pour inte´grer de nouveaux mode`les
de diagnostic de la TB. Nous utilisons ce cadre pour
de´crire les priorite´s de la mode´lisation dans quatre
domaines principaux : l’expansion du test XpertwMTB/
RIF, le ciblage de produits pour de nouveaux tests, les
tests de pharmaco-sensibilite´ afin d’e´laborer de
nouveaux protocoles the´rapeutiques et la ne´cessite´
d’ame´liorer les mode`les futurs de diagnostic de la TB.
Si nous voulons maximiser l’impact et la rentabilite´ du
diagnostic de la TB, ces priorite´s doivent eˆtre les cibles
principales de la recherche future.
R E S UM E N
El panorama de las pruebas diagno´sticas de la
tuberculosis (TB) esta´ evolucionando ra´pidamente y
los interesados directos precisan con urgencia directrices
en materia de desarrollo, despliegue y optimizacio´n de
estos me´todos, de manera que se obtenga el ma´ximo
impacto, mediante el uso o´ptimo de los recursos
existentes. Cuando se deben adoptar decisiones solo
con base en datos incompletos o preliminares, la
modelizacio´n aparece como un instrumento u´til que
puede aportar esta orientacio´n. Tras una reunio´n con
modeladores y otros interesados clave, organizada por el
‘TB Modelling and Analysis Consortium’, se propuso un
marco teo´rico destinado al posicionamiento de los
modelos de pruebas diagno´sticas de la TB. A partir de
este marco, se describen las prioridades de la
modelizacio´n en cuatro esferas principales: las
estrategias de ampliacio´n de escala de la prueba
Xpertw MTB/RIF, la definicio´n de las caracterı´sticas
de las nuevas pruebas, las pruebas de sensibilidad a los
medicamentos que fundamenten los nuevos regı´menes
terape´uticos y las deficiencias que se deben superar a fin
de mejorar los futuros modelos de me´todos diagno´sticos
de la TB. Si se busca obtener el ma´ximo impacto y la
mayor rentabilidad de los medios diagno´sticos, estas
prioridades de modelizacio´n deben ocupar un puesto
prominente en los objetivos de las investigaciones
futuras.
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